Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

MUCOBIOME-MEDIATED IMMUNE PATHWAYS IN INFLAMMATORY BOWEL DISEASES

Project description

Intestinal mucus degradation in inflammatory bowel disease

Inflammatory bowel disease (IBD) is a rising global health concern that presents with persistent ulcerations in the gastrointestinal tract. Although a low-fibre diet and the gut microbiota seem to contribute to the disease, the precise mechanisms are poorly understood. The EU-funded MUCO-IMMUN project focusses on the bacteria known as the mucobiomes, which use enzymes to digest the host intestinal mucus layer, acting as the first line of defence against pathogens. Since dietary fibre regulates the mucolytic activities of these bacteria, scientists are working under the hypothesis that mucobiomes play a role in IBD pathogenesis. Identification of the immune pathways that are deregulated in IBD will aid the design of innovative diet-based therapies.

Objective

Inflammatory Bowel Diseases (IBD) are chronic disorders characterized by persistent ulcerations in the gastrointestinal tract, drastically affecting the patient’s quality of life. Initially regarded as “Western diseases”, they have now become a global problem. Despite IBD being a set of inflammatory diseases, the underlying host immune pathways remain unclear, making it difficult to reliably treat and cure patients. The low-fiber Western diet, and the microbial communities that live in our intestines (the gut “microbiome”), have been proposed as major environmental contributors of the disease - but the mechanisms of their contribution are poorly understood.
Among the gut microbiome, the mucobiomes are defined as the microbial communities enzymatically geared to digest the host intestinal mucus layer – our first line of defense against invading pathogens. Their mucolytic activities are regulated by dietary fibers. Thus, we hypothesize that, under a low-fiber diet, the mucobiomes catalyze important disease-promoting immune pathways of IBD. Using an original animal model combining genetic susceptibility, dietary fiber deficiency and different microbiota compositions, we aim at highlighting (1) the role of the mucobiome in IBD pathogenesis, and (2) key immune-pathways regulated by the mucobiome. These objectives are ambitious, yet highly feasible given the expertise of the actors. The proposed work provides a unique dimension to understand the underlying pathogenic mechanisms of a key physiological trait of gut bacteria: host-secreted mucus degradation. The success of this project relies on a close interdisciplinary collaboration that will benefit to develop the researcher's career, the hosting group’s projects, the hosting institute's visibility, and establish innovative diet-based therapies for IBD patients.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)

See all projects funded under this funding scheme

Call for proposal

(opens in new window) H2020-MSCA-IF-2019

See all projects funded under this call

Coordinator

LUXEMBOURG INSTITUTE OF HEALTH
Net EU contribution
€ 166 320,00
Address
1A RUE RUE THOMAS EDISON
1445 Strassen
Luxembourg
Region
Luxembourg Luxembourg Luxembourg
Activity type
Research Organisations
Links
Total cost
€ 166 320,00